欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

乳腺癌中抑制EGFR-DNA损伤的组合治疗系统级研究

Systems-Level Analysis of EGFR Inhibition-DNA Damage Combination Treatment in Breast Cancer.
作者:Lee, M. J. 作者单位:Massachusetts Inst. of Tech., Cambridge. 加工时间:2014-08-22 信息来源:科技报告(AD ) 索取原文[62 页]
关键词:化疗;雌激素;曝光(生理学);孕激素;受体位点(生理学);乳腺癌细胞(生物)
摘 要:Triple-negative breast cancer (TNBC) is a heterogeneous mix of cancers defined only by the absence of the three best-characterized prognostic markers: estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). This lack of understanding underlies our inability to identify effective therapeutic options for these patients. During the previous research period for this award (year 1), we identified that a subset of TNBCs have high baseline levels of activated EGFR, and were sensitive to certain temporal combinations of EGFR inhibition and DNA damaging chemotherapy. The focus of this research period (year 2) was to determine the mechanism of this enhanced sensitivity to chemotherapy. Using an integrative analysis of multiple signaling networks, we identified that chronic exposure to EGFR inhibition in a subset of TNBCs resulted in a profound genetic rewiring, resulting in more than 2000 differentially expressed genes (DEGs). Further analyses revealed that caspase-8 played a crucial role in the combination therapy we identified, a surprising and unexpected finding, since this protein was not previously thought to contribute to DNA damage-induced cell death. Collectively, these findings identify a novel method for enhancing chemotherapeutic efficacy, through rewiring apoptotic signaling networks.
© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服